Anti-platelet therapy and endoscopic procedures: eyes wide shut?

Cesare Hassan, Angelo Zullo

Department of Gastroenterology, ONRM Hospital, Rome, Italy

That the decision-making process in medicine is generally complex is comprehensible. Indeed, several factors need be considered when a medical procedure is performed or a therapeutic approach is used, such as the patient’s characteristics, the complexity of the procedure, the drugs to be administered, the physician’s skill, and the setting. The difficulty is further increased when the available scientific data for a specific topic are incomplete or controversial. In this scenario, the existence of official guidelines is surely an advantage for physicians wishing to minimize clinical errors.

The management of antiplatelet agent (APA) therapy before gastrointestinal endoscopy is a typical situation requiring complex analysis in that several factors need to be considered. Fortunately, in 2009, the American Society of Gastrointestinal Endoscopy (ASGE) Standards of Practice Committee delivered recommendations on the management of antithrombotic agents in patients undergoing endoscopic procedures [1]. Basically, the endoscopic examinations were subgrouped as procedures associated with a “low risk” or a “high risk” for bleeding. The recommendations advised that the discontinuation of APA therapy before diagnostic procedures (low risk), as well as before polypectomy, endoscopic retrograde pancreatography (ERCP) with sphincterotomy, stent placement (without dilation), and percutaneous endoscopic gastrostomy (PEG), is not required because no data have consistently demonstrated a significant increase in risk for bleeding [1]. Moreover, no bleeding-related deaths occurred in patients on APA therapy after endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) [2, 3]. Nevertheless, the question of how these guidelines are followed in clinical practice must be asked. A specific, pretested questionnaire was administered to 400 gastroenterologists attending an ASGE endoscopy course, and 239 of them (60%) completed the survey [4]. Surprisingly, as many as 26% of the endoscopists stated that they withhold all APAs before any endoscopic procedure. Such an approach raises some relevant concerns, which deserve consideration.

As in a movie, we alternately look at a case with the eyes of an endoscopist and with those of a patient. The endoscopist is required to perform an endoscopic procedure in a patient at increased risk for bleeding because of ongoing APA therapy. What are the endoscopist’s eyes looking at? Surely, procedure-related bleeding. Therefore, the endoscopist stops the APA therapy for 5 to 7 days before the endoscopic procedure (and for 1 to 5 days afterward) in all patients, particularly when he or she considers that an unplanned operative procedure (e.g., a polypectomy) may be necessary. Although such a cautious approach is also advantageous for the patient, the endoscopist is marginalizing the potential risk to the patient related to the interruption of APA therapy. Indeed, the patient is taking long-term APA therapy for either the primary or the secondary prevention of cardiovascular events. Prevention is primary when a patient has cardiovascular risk factors but has previously had no cardiovascular event, whereas it is secondary when a patient has previously had a myocardial infarction or stroke. What are the patient’s eyes are looking at when the interruption of preventive therapy is suggested? Surely, they are imagining a serious cardiovascular event. Most likely, the patient is unaware of the increased risk for bleeding during endoscopy that is related to the ongoing APA therapy. How to balance the caution of the endoscopist and the safety of the patient? Considering that the ideal situation (a zero risk for bleeding and a zero risk for a cardiovascular event) is impossible, a wise approach should be chosen. Fortunately, consistent data are available on the role of APA therapy in the prevention of cardiovascular events. There is clear evidence that the cardiovas-
cullar risks are distinctly different in the settings of primary and secondary prevention [5]. As shown in Table 1, the risk for ischemic events (myocardial infarction and stroke) without therapy is nearly 10-fold higher in secondary than in primary prevention (3.11 % vs 0.34 % yearly).

Based on these data, APA therapy can be safely interrupted for 5 to 7 days in those patients receiving primary prevention, but not in those receiving secondary prevention. Of note, nearly 70 % of recurrent cardiovascular events develop within 7 to 10 days after the interruption of therapy, suggesting a potential “aspirin withdrawal syndrome” due to a probable rebound in platelet function [6]. Moreover, in a randomized study of patients on APA therapy for secondary cardiovascular prevention in whom endoscopic hemostasis of an actively bleeding peptic ulcer was achieved, it was found that a cardiovascular complication developed in 6.4 % of those receiving placebo, and as many as 60 % of these complications occurred within 10 days [7]. Therefore, even a short interruption of APA therapy is associated with a risk for cardiovascular complications, with potentially life-threatening consequences.

Of note, the risk for delayed bleeding requiring re-intervention following colonic polypectomy was 6.4 % in patients taking clopidogrel and 5.5 % in patients taking aspirin [8, 9]. These rates are very similar to the rate of cardiovascular complications following the withdrawal of APA therapy [7]. However, the clinical consequences are not the same. Indeed, unlike post-procedural bleeding, which is preventable, can be managed successfully in the large majority of cases, and does not cause long-term consequences, a cardiovascular event cannot be prevented, is associated with a high morbidity rate, and may cause irreversible disability. It would be very interesting to know whether the 26 % of endoscopists who stated that they withhold all APAs before any endoscopic examination withhold them from patients undergoing dual therapy with ASA and clopidogrel after the placement of a drug-eluting coronary stent. In these patients, APA interruption is really dreadful. Indeed, operative endoscopy in these patients should be either postponed, when possible, or performed while the patient is on bridging antithrombotic therapy with tirofiban (Aggrastat; Medicure Pharma) in urgent situations [10], but APA interruption must be avoided.

Another relevant finding of this survey is that the endoscopists who stopped APA therapy before any endoscopic examination based the decision on their own experience without witnessing ischemic or bleeding complications, suggesting an “a priori” choice [4]. Probably, the cardiovascular risks related to the interruption of APA therapy, particularly in those patients receiving secondary prevention, were neglected or unjustifiably marginalized by the endoscopists.

At the end of the movie, the endoscopist is seeing “red” (bleeding) and the patient is seeing “black” (dead after a cardiovascular event), leading to the paradox of an “eyes wide shut” scenario. A possible solution is to keep in mind that in secondary cardiovascular prevention, the risk for bleeding related to the continuation of APA therapy before an operative endoscopic procedure is, in absolute terms, equivalent to the risk for a cardiovascular complication. On the other hand, with APA therapy, the patient is already accepting a risk for hemorrhagic stroke (0.17 % yearly) similar to that for gastrointestinal bleeding (0.11 % yearly).

Thus, just accept for the gastrointestinal tract the same absolute risk for bleeding that you already accept for the brain, but save the heart!

Competing interests: None

References
1 Anderson MA, Ben-Menachem T. AGSE Standards of Practice Committee et al. Management of anti-thrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060–1070

Table 1 Annual rates of cardiovascular events in patients receiving primary or secondary prevention with antiplatelet therapy.

<table>
<thead>
<tr>
<th>Setting*</th>
<th>Nonfatal myocardial infarction, %</th>
<th>Ischemic stroke, %</th>
<th>Hemorrhagic stroke, %</th>
<th>Major GI bleeding, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ASA C OR (95 %CI)</td>
<td>ASA C OR (95 %CI)</td>
<td>ASA C OR (95 %CI)</td>
<td>ASA C OR (95 %CI)</td>
</tr>
<tr>
<td>Primary prevention</td>
<td>0.18 0.23 0.77 (0.69 – 0.86)</td>
<td>0.10 0.11 0.86 (0.74 – 1.00)</td>
<td>0.04 0.03 1.32 (1.00 – 1.75)</td>
<td>0.10 0.07 1.54 (1.30 – 1.82)</td>
</tr>
<tr>
<td>Secondary prevention</td>
<td>1.66 2.34 0.69 (0.60 – 0.80)</td>
<td>0.61 0.77 0.78 (0.61 – 0.99)</td>
<td>0.17 0.09 1.67 (0.97 – 2.90)</td>
<td>0.11 0.03 2.69 (1.25 – 5.76)</td>
</tr>
</tbody>
</table>

GI, gastrointestinal; ASA, low-dose aspirin; OR, odds ratio; CI, confidence interval.

* Primary prevention: in patients with cardiovascular risk factors but without a previous cardiovascular event; secondary prevention: in patients with a previous myocardial infarction or stroke.